… We review the current status of group A streptococcal vaccines. ► We describe obstacles
to streptococcal vaccine development. ► We detail a path for accelerated vaccine …

Group A streptococcal (GrAS) infections continue to pose a significant threat to human health.
It is estimated that annually in the United States there are approximately 15 million cases …

Several vaccine candidates against GAS infection are in varying stages of preclinical and
clinical development. Although there is great hope that one of these vaccine candidates will …

JAMES B. DALE, MD he search for a safe and effective vaccine against group A beta-hemolytic
streptococcal (GABHS) infections has been ongoing for over 60 years. There are …

Group A Streptococcus (GAS) infections are a significant global cause of morbidity and
mortality. GAS diseases disproportionally affect those living in conditions characterized by …

Numerous attempts to immunize humans against GAS infections date back to the 1930s,
when dead GAS intravenously administered to children who had rheumatic fever reportedly …

Group A streptococci are model extracellular gram-positive pathogens responsible for
pharyngitis, impetigo, rheumatic fever, and acute glomerulonephritis. A resurgence of invasive …

… He is the inventor of certain technologies related to the development of group A streptococcal
vaccines. The University of Tennessee has licensed the technology to Vaxent, LLC, of …

Substantial morbidity and mortality due to group A Streptococcus (GAS) diseases persist
worldwide, yet development of safe and effective vaccines has been impeded by scientific, …

Group A streptococcus (GAS) is associated with many human diseases, ranging in severity
from benign to life-threatening. A promising strategy for developing vaccines against GAS …